, Volume 13, Issue 1, pp 74-83

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



The importance of establishing hormone receptor status of tumors for the treatment of women with hormone receptor-positive breast cancer has been emphasized, however, there is no general agreement as to how immunohistochemical assays should be evaluated. It is critical to evaluate hormone recptor status when considering response to endocrine therapy.


Estrogen receptor (ER) and progesterone receptor (PgR) expression was examined by immunohistochemistry using Allred’s score for primary breast tumors from 75 metastatic breast cancer patients who received first-line treatment with endocrine therapy (56 patients received tamoxifen, 11 patients received aromatase inhibitors, and 8 patients received LH-RH agonist or other endocrine reagents) on relapse. Correlation between hormone receptor status and response to endocrine therapy as well as post-relapse survival was analyzed.


The most significant correlation between positive ER expression and response to any endocrine therapy (p=0.011) or tamoxifen only (p=0.030) occurred when the cutoff score was set at 10%. When the evaluation was based on Allred’s score (TS), a cutoff point of TS ≧4 showed a more significant association between positive ER expression and response to all kinds of endocrine therapy (p=0.020) or tamoxifen only (p=0.047). When evaluated at a cutoff point of 1% positive cells, there were fifteen patients with both ER- and PgR-negative tumors, and three patients (20.0%) responded to the therapy. Patients with 1% or more ER or PgR positive cells had better survival after relapse (p=0.0005 andp=0.0008, respectively).


The proportion score alone might be enough to predict hormone responsiveness and post-relapse survival in metastatic breast cancer. The cutoff might be set low, for example 1%, especially for metastatic disease.